Prevalence of Nonalcoholic Fatty Liver Disease in Familial Mediterranean Fever.
Adult
Body Mass Index
Case-Control Studies
Dyslipidemias
/ complications
Familial Mediterranean Fever
/ complications
Female
Humans
Inflammation
/ complications
Insulin Resistance
/ physiology
Male
Metabolic Syndrome
/ complications
Middle Aged
Non-alcoholic Fatty Liver Disease
/ complications
Prevalence
Turkey
/ epidemiology
Ultrasonography
Young Adult
Familial Mediterranean fever
dyslipidemia
inflammation
insulin resistance
metabolic syndrome
nonalcoholic fatty liver disease
Journal
Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
12
2019
revised:
16
01
2020
accepted:
20
01
2020
pubmed:
23
2
2020
medline:
4
6
2021
entrez:
21
2
2020
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome (MetS), insulin resistance (IR) and chronic inflammation. Although familial Mediterranean fever (FMF) patients have no symptoms in the periods between attacks, their subclinical inflammation continues. The aim of the present study was to determine the NAFLD frequency in FMF patients and to evaluate their MetS, IR and lipid profiles. The study included 54 FMF patients and 54 control subjects. The clinical and demographic characteristics of the subjects were recorded, and the patients' Pras disease severity score was calculated. IR was determined using the homeostasis model assessment (HOMA) index. MetS was diagnosed using the revised National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP ATP III). Hepatic ultrasonography was used to diagnose NAFLD. NAFLD was observed in 15 FMF patients (27.8%) and 14 controls (25.9%). The difference between the groups was not significant (p=0.828). Similarly, no significant difference was found between the two groups for MetS frequency and HOMA index levels. Fasting plasma glucose was significantly higher in FMF patients, whereas differences between the two groups were not significant for lipid levels and other parameters. When FMF patients with and without NAFLD were compared, no significant difference was found in Pras disease severity score, duration of the disease and daily colchicine dose. The present study showed that NAFLD frequency was not increased in FMF patients, and that patients' MetS frequency, IR and lipid profiles were not different from control subjects.
Identifiants
pubmed: 32077835
pii: EMIDDT-EPUB-104696
doi: 10.2174/1871530320666200220125829
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
952-958Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.